Skip to content

Study · Not a test of the peptide alone · 2023

3 results

Glucometabolic control of once-weekly dulaglutide switched from DPP4 inhibitor versus daily empagliflozin add-on in patients with type 2 diabetes inadequately controlled with metformin, sulfonylurea, and DPP4 inhibitor: A randomised trial.

Lee EY, Cho JH, Lee WJ, Kim NH, Kim JH, Lee BW

Diabetes research and clinical practice16 Aug 2023Cited by 5 (Europe PMC)

PMID37595844 (opens in a new tab)DOI10.1016/j.diabres.2023.110884 (opens in a new tab)PepBankPUB-37595844
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone3

In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Dulaglutide (Trulicity).

  1. 01HumanNot a test of Dulaglutide (Trulicity) aloneRandomized controlled trialEfficacy outcome

    In T2D patients, switching DPP4 inhibitor to dulaglutide produced less HbA1c reduction than adding empagliflozin to the existing regimen.

    In plain wordsIn people with diabetes, switching to dulaglutide reduced HbA1c less than adding empagliflozin to the existing regimen.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    IncreaseHbA1c between regimens
    Study

    n = 152

    Comparator
    Empagliflozin added to metformin, sulfonylurea and DPP4 inhibitor
    Analysis
    Primary
    Outcome group
    Glycemic control · Metabolic and weight

    Measurements

    Mean treatment difference in HbA1c (empagliflozin vs dulaglutide)
    −0.27%
    95% CI -0.50 to -0.04, week 24
    Mean treatment difference in HbA1c (empagliflozin vs dulaglutide)
    −2.88 mmol/mol
    95% CI -5.37 to -0.39, week 24

    Source sentences

    Summary
    At week 24, both groups showed significant reduction in HbA1c level from baseline with greater reduction with empagliflozin (the mean treatment difference: -0.27% [95% CI -0.50 to -0.04, p = 0.024]) (-2.88 mmol/mol [95% CI -5.37 to -0.39], p = 0.024).
    1 context sentence
    Summary · context
    In this 24-week, multi-center, randomized trial, patients with T2D and HbA1c level ≥7.5% (58 mmol/mol) on metformin, sulfonylurea, and dipeptidyl peptidase 4 inhibitor (DPP4-i)

    In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).

  2. 02HumanNot a test of Dulaglutide (Trulicity) aloneRandomized controlled trialEfficacy outcome

    In T2D patients, the regimen switching DPP4 inhibitor to dulaglutide reduced HbA1c from baseline.

    In plain wordsIn people with diabetes, switching DPP4 inhibitor to dulaglutide within triple therapy reduced HbA1c from baseline.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseHbA1c change from baseline
    Study

    n = 76

    Comparator
    Baseline
    Analysis
    Primary
    Outcome group
    Glycemic control · Metabolic and weight

    Source sentences

    Summary
    At week 24, both groups showed significant reduction in HbA1c level from baseline
    2 context sentences
    Summary · context
    In total, 152 patients were recruited to the empagliflozin-added quadruple group (n = 76) or the switched-to-dulaglutide triple group (n = 76).
    Summary · context
    In this 24-week, multi-center, randomized trial, patients with T2D and HbA1c level ≥7.5% (58 mmol/mol) on metformin, sulfonylurea, and dipeptidyl peptidase 4 inhibitor (DPP4-i)

    In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).

  3. 03HumanNot a test of Dulaglutide (Trulicity) aloneRandomized controlled trialSafety outcome

    In patients with T2D, no serious adverse events were reported with dulaglutide switched from DPP4 inhibitor or with empagliflozin add-on.

    In plain wordsIn people with diabetes, no serious adverse events were reported in either the dulaglutide switch group or the empagliflozin add-on group.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    Not applicableSerious adverse events
    Study

    n = 76

    Comparator
    Empagliflozin added to metformin, sulfonylurea and DPP4 inhibitor
    Outcome group
    Adverse events · Whole body

    Source sentences

    Summary
    No serious adverse events were reported with either empagliflozin or dulaglutide.
    1 context sentence
    Summary · context
    In this 24-week, multi-center, randomized trial, patients with T2D and HbA1c level ≥7.5% (58 mmol/mol) on metformin, sulfonylurea, and dipeptidyl peptidase 4 inhibitor (DPP4-i)

    In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:25 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.